SAB Biotherapeutics Inc.

NASDAQ: SABS · Real-Time Price · USD
2.19
-0.02 (-0.90%)
At close: Aug 15, 2025, 3:59 PM
2.21
0.91%
After-hours: Aug 15, 2025, 06:08 PM EDT

SAB Biotherapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
1.32M 2.24M 23.9M 60.88M
Cost of Revenue
4.79M 3.75M 3.29M 1.65M
Gross Profit
-3.47M -1.51M 20.61M 59.22M
Operating Income
-42.91M -38.08M -28.92M -13.39M
Interest Income
1.29M 584.97K 71.07K 23.11K
Pretax Income
-34.1M -42.19M -18.71M -17.14M
Net Income
-34.1M -42.19M -18.74M -17.14M
Selling & General & Admin
13.98M 23.8M 16.38M 17.09M
Research & Development
30.25M 16.52M 36.44M 57.18M
Other Expenses
-70 -3.75M -3.29M -1.65M
Operating Expenses
44.23M 36.57M 49.53M 72.62M
Interest Expense
318.4K 315.28K 301.58K 294.46K
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
44.23M 40.31M 52.82M 74.27M
Income Tax Expense
n/a n/a 25.63K n/a
Shares Outstanding (Basic)
9.26M 5.52M 4.35M 4.35M
Shares Outstanding (Diluted)
9.26M 5.52M 4.35M 2.73M
EPS (Basic)
-3.68 -7.64 -4.31 -3.94
EPS (Diluted)
-3.68 -7.64 -4.31 -6.3
EBITDA
-28.99M -38.13M -15.12M -15.2M
EBIT
-33.79M -41.88M -18.41M -16.85M
Depreciation & Amortization
4.79M 3.75M 3.29M 1.65M